Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

17 results
Display

NUDT15 gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease

Matsuoka K

Thiopurine has been used to maintain remission and to reduce antidrug antibody formation in monoclonal antibody therapy in patients with inflammatory bowel disease (IBD). The use of thiopurine is limited...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Diet, microbiota, and inflammatory bowel disease: lessons from Japanese foods

Kanai T, Matsuoka K, Naganuma M, Hayashi A, Hisamatsu

  • KMID: 2070102
  • Korean J Intern Med.
  • 2014 Jul;29(4):409-415.
The incidence and prevalence of inflammatory bowel diseases (IBDs) including ulcerative colitis and Crohn disease are rapidly increasing in Western countries and in developed Asian countries. Although biologic agents targeting...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis

Matsuoka K, Togo K, Yoshii N, Hoshi M, Arai S

Background/Aims: Patients with ulcerative colitis (UC) are at an increased risk of certain infections and malignancies compared with the general population. Incidence rates (IRs) of hospitalized infections, herpes zoster (HZ),...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tacrolimus for the Treatment of Ulcerative Colitis

Matsuoka K, Saito E, Fujii T, Takenaka K, Kimura M, Nagahori M, Ohtsuka K, Watanabe M

Tacrolimus is a calcineurin inhibitor used for the treatment of corticosteroid-refractory ulcerative colitis (UC). Two randomized controlled trials and a number of retrospective studies have assessed the therapeutic effect of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Magnetic resonance enterography for the evaluation of the deep small intestine in Crohn's disease

Ohtsuka K, Takenaka K, Kitazume Y, Fujii T, Matsuoka K, Kimura M, Nagaishi T, Watanabe M

For the control of Crohn's disease (CD) a thorough assessment of the small intestine is essential; several modalities may be utilized, with cross-sectional imaging being important. Magnetic resonance (MR) enterography,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Fecal microbiota transplantation for recurrent Clostridium difficile infection in a patient with ulcerative colitis

Nanki K, Mizuno S, Matsuoka K, Ono K, Sugimoto S, Kiyohara H, Arai M, Nakashima , Takeshita , Saigusa K, Senoh M, Fukuda T, Naganuma M, Kato H, Suda W, Hattori M, Kanai T

Fecal microbiota transplantation (FMT) has been reported as a safe and effective therapy in patients with refractory and recurrent Clostridium difficile infection (CDI). FMT has also been reported as a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Production of cloned sei whale (Balaenoptera borealis) embryos by interspecies somatic cell nuclear transfer using enucleated pig oocytes

Lee E, Bhuiyan MM, Watanabe H, Matsuoka K, Fujise Y, Ishikawa H, Fukui Y

In this study, we examined the feasibility of using subzonal cell injection with electrofusion for interspecies somatic cell nuclear transfer (iSCNT) to produce sei whale embryos and to improve their...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis

Miyoshi J, Matsuoka K, Yoshida A, Naganuma M, Hisamatsu , Yajima T, Inoue N, Okamoto S, Iwao Y, Ogata H, Ueno F, Hibi T, Kanai T

Ulcerative colitis (UC) is one of the major clinical phenotypes of inflammatory bowel diseases. Although 5-aminosalicylic acid (5-ASA) is widely used for UC and its efficacy and safety have been...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Vaccination in patients with inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting

Park SB, Kim KO, Lee HS, Choi CH, Wei SC, Chen MH, Matsuoka K

Background/Aims: Long-term immunosuppressive therapies used to treat inflammatory bowel disease (IBD) are associated with an increased risk of infections, many of which can be prevented by vaccination. We assessed physicians’...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives-

Kwon J, Kim DY, Cho KJ, Hashimoto M, Matsuoka K, Kamijo T, Wang Z, Karnup S, Robertson AM, Tyagi P, Yoshimura N

Overactive bladder (OAB) is a symptom-based syndrome defined by urinary urgency, frequency, and nocturia with or without urge incontinence. The causative pathology is diverse; including bladder outlet obstruction (BOO), bladder...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immunological Abnormalities in the Pathogenesis of Inflammatory Bowel Disease

Hisamatsu , Mikami Y, Matsuoka K, Kanai T, Hibi T

Crohn's disease and ulcerative colitis represent two distinct forms of inflammatory bowel diseases (IBD). In this paper, we discuss how immunological mechanisms contribute to the pathogenesis of IBD. Intestinal homeostasis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial

Hibi T, Motoya S, Hisamatsu T, Hirai F, Watanabe K, Matsuoka K, Saruta M, Kobayashi T, Feagan BG, Tasset C, Besuyen R, Yun C, Crans G, Zhang J, Kondo A, Watanabe M

Background/Aims: The safety and efficacy of filgotinib, a once-daily oral Janus kinase 1 preferential inhibitor, were evaluated in Japanese patients with ulcerative colitis (UC) in the phase 2b/3 SELECTION trial. Methods:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Single fecal microbiota transplantation failed to change intestinal microbiota and had limited effectiveness against ulcerative colitis in Japanese patients

Mizuno S, Nanki K, Matsuoka K, Saigusa K, Ono K, Arai M, Sugimoto S, Kiyohara H, Nakashima , Takeshita , Naganuma M, Suda W, Hattori M, Kanai T

BACKGROUND/AIMS: Recent developments in analytical techniques including next-generation sequencing have clarified the correlation between intestinal microbiota and inflammatory bowel disease. Fecal microbiota transplantation (FMT) for patients with ulcerative colitis (UC)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
β-(1,3)-Glucan derived from Candida albicans induces inflammatory cytokines from macrophages and lamina propria mononuclear cells derived from patients with Crohn's disease

Mori K, Naganuma M, Mizuno S, Suzuki H, Kitazume M, Shimamura , Chiba S, Sugita A, Matsuoka K, Hisamatsu , Kanai T

BACKGROUND/AIMS: Recent research has highlighted the importance of interactions between commensal fungi and intestinal inflammation. However, there are few studies investigating whether commensal fungi contribute to inflammation in patients with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan

Komoto S, Motoya S, Nishiwaki , Matsui T, Kunisaki R, Matsuoka K, Yoshimura , Kagaya T, Naganuma M, Hida N, Watanabe M, Hibi T, Suzuki Y, Miura S, Hokari R, Japanese study group for pregnant women with IBD

BACKGROUND/AIMS: Anti-tumor necrosis factor drugs (anti-TNF) and thiopurines are important treatment options in patients with inflammatory bowel disease (IBD), including during pregnancy. However, there are limited data on the benefit/risk...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management

Park DI, Hisamatsu , Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK

Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment

Park DI, Hisamatsu , Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK

Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr